Rockwell Collins to Sell Kaiser Optical Systems to Endress+Hauser - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Rockwell Collins to Sell Kaiser Optical Systems to Endress+Hauser

Rockwell Collins announced that it has agreed to sell its subsidiary, Kaiser Optical Systems, a spectrographic instrumentation and applied holographic technology company, to Endress+Hauser, a producer of measurement instrumentation and services for industrial process engineering. Terms of the agreement were not disclosed. The sale is expected to be complete in early fiscal 2014 and is subject to customary closing conditions.

Kaiser Optical Systems, located in Ann Arbor, Michigan, became a Rockwell Collins company in 2000 as part of the company’s purchase of K Systems, the parent company of Kaiser Aerospace and Electronics. Principal products include Raman sensors and instrumentation, advanced holographic components for
spectroscopy, telecommunications, astronomy and ultra-fast sciences, and components for aircraft display systems.

Source: Rockwell Collins


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns

Click here